BURLINGTON, MASS. – Mirus Capital Advisors, one of New England’s largest independent middle-market investment banks, has advised Oxipit, a developer of clinically validated AI solutions for radiology, on its acquisition by Sectra, an international medical imaging IT and cybersecurity company headquartered in Linköping, Sweden.
Based in Vilnius, Lithuania and founded in 2017, Oxipit holds the first CE Class IIB certification for autonomous AI in chest X-ray analysis. Its ChestLink solution automatically identifies high-confidence normal examinations and removes them from the radiologist’s worklist, enabling specialists to focus on cases that require their clinical judgment.
“Choosing an advisor for a transaction of this complexity was a significant decision,” said Peter Corscadden, CEO of Oxipit at the time of the transaction. “Following an extensive search, Mirus earned our confidence with the depth of their senior team, their genuine understanding of autonomous radiology AI, and the discipline they brought to every stage of the process. Their partners were engaged and hands-on throughout, treating our technology and our mission with the seriousness both deserved. Their guidance was instrumental in identifying Sectra as the right home for Oxipit, and we are grateful for their partnership throughout.”
“We congratulate Oxipit on building and delivering a differentiated and pioneering autonomous radiology AI platform,” said Brendan Kiernan, Partner with Mirus Capital Advisors. “It was a pleasure to work with the team on this successful transaction, and we look forward to watching them continue to scale the business alongside a strong partner in Sectra.”
Alan Fullerton, Mirus Capital Advisors Chairman and CEO, added, “AI-driven diagnostic platforms sit at the intersection of two of the most innovative sectors: Healthcare and Technology. We’re excited to support the ongoing developments in this space.”
Transaction Leaders
About Sectra
Sectra contributes to a healthier and safer society by assisting health systems throughout the world to enhance the efficiency of care, and authorities and defense forces in Europe to protect society’s most sensitive information. The company, founded in 1978, is headquartered in Linköping, Sweden, with direct sales in 19 countries, and distribution partners worldwide. Sales in the 2024/2025 fiscal year totaled SEK 3,240 million. The Sectra share is quoted on the Nasdaq Stockholm exchange. For more information, visit Sectra’s website.
About Oxipit
Founded in 2017 by experts in medicine and data science, Oxipit is a leader in AI-based medical imaging. The company introduced ChestEye in 2019 for detection of 75 chest X-ray findings and launched ChestLink in 2022 as the world’s first CE Class IIb certified solution capable of identifying normal chest X-rays with 99.9% sensitivity. In 2026, Oxipit expanded its portfolio into chest CT and musculoskeletal X-ray imaging, continuing to support radiologists through workflow-integrated detection, prioritisation, and reporting support in daily clinical practice worldwide. Read more at oxipit.ai.
About Mirus Capital Advisors
Mirus Capital Advisors is a premier independent middle-market investment bank delivering sophisticated transaction advice with precision execution and proven results. With close to 40 years of experience and 450+ completed transactions, Mirus provides M&A advisory, capital raising, and fairness opinion and valuation services to corporations, private equity firms, public companies, and boards of directors across the technology, industrial, business services, healthcare and life sciences, and consumer sectors. The firm’s experienced team leverages deep industry expertise, established relationships, and global reach through its international network to broaden possibilities and deliver premium outcomes for clients. Mirus has earned national recognition for excellence in the middle market, including multiple Deal of the Year honors. For more, visit www.merger.com.
About Mirus